Netscientific Share Discussion Threads

[k1ngkonggb] 19/1/2022 15:37

Looks like another one for the bottom draw!!!!!

[peaky01] 18/1/2022 22:55

Logically that makes sense but from memory even when pdsb was 16dollars we were abou 1.10 here....

[thiopia] 18/1/2022 21:29

PDSB our biggest listed investment is down around 60-70% from its recent peak

No surprise this is doing badly.

Added to failures to maintain newsflow on other major investments

[kingston78] 18/1/2022 21:00

Investors buy and investors sell. They buy or sell for their own reasons. Sometimes it has nothing to do with fundamentals of a company. What I would say is that patience will be rewarded.

[blakieboy7] 18/1/2022 18:16

A very disappointing day loaf

[loafofbread] 18/1/2022 17:46

Assume todays TR1 explains the recent weakness?

[loafofbread] 14/1/2022 11:48

One of ours.

G-Tech Medical Receives FDA Clearance for its Gastrointestinal Motility Monitoring System
Published: Jan 13, 2022

MOUNTAIN VIEW, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- G-Tech Medical, a developer of non-invasive diagnostic solutions for patients with gastrointestinal disorders, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Wireless Patch System (WPS) for non-invasive myoelectric activity measurement.

The G-Tech WPS is a tool that provides gastric and intestinal myoelectrical activity measurements to be used at the discretion of the Physician or Clinical researcher to aid in the diagnosis and evaluation of gastrointestinal disorders.

“We are excited to receive our first regulatory clearance,” said Steve Axelrod, CEO of G-Tech. “This is a key achievement in support of our ultimate goal of providing a motility solution that localizes the sources and identifies the nature of GI disorders.”

Gastrointestinal (GI) motility is the underlying factor in a wide range of disorders and dysfunction experienced by tens of millions in the U.S. GI disorders include inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and other functional gastrointestinal disorders (FGID’s).1 GI dysfunctions are also prevalent during recovery from abdominal surgery which can lead to post-operative ileus (POI).2

Current motility technologies are typically limited in scope, invasive and only sample for a brief time period in a non-physiological setting, such as a hospital or physician office. The G-Tech product, in contrast, measures myoelectrical signals from the stomach, small intestines and colon over multiple days non-invasively in a variety of settings.

G-Tech will continue to prioritize investment in clinical trials in the near term.

“It’s all about the data. Developing a large, proprietary data set which we can mine and analyze to drive new learnings, and correlate motility with specific GI issues, is key for us,” said Axelrod. “We truly believe our ‘EKG for the Gut’ will become a standard of care in gastroenterology over time. Growing our patient motility database is the shortest path to that future.”

Peery AF, Crockett SD, Murphy CC, Lund JL, Dellon ES, Williams JL, Jensen ET, Shaheen NJ, Barritt AS, Lieber SR, Kochar B, Barnes EL, Fan YC, Pate V, Galanko J, Baron TH, Sandler RS. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. Gastroenterology. 2019 Jan;156(1):254-272.e11. doi: 10.1053/j.gastro.2018.08.063. Epub 2018 Oct 10. Erratum in: Gastroenterology. 2019 May;156(6):1936. PMID: 30315778; PMCID: PMC6689327.
Nachlas, MARVIN M., M. Tewfic Younis, C. Pio Roda, and JOSEPH J. Wityk. "Gastrointestinal motility studies as a guide to postoperative management." Annals of surgery 175, no. 4 (1972): 510.
About G-Tech Medical
G-Tech Medical, Inc. is an early-stage medical device company dedicated to developing low-cost, non-invasive gastrointestinal monitoring solutions for patients with chronic GI disorders. G-Tech’s wearable wireless patch will provide patient-specific motility data to physicians, helping them assess underlying causes of GI disorders and develop targeted therapies. The company is headquartered at Fogarty Innovation, 2495 Hospital Drive, Suite 300, Mountain View, CA 94040. For further information, please visit www.GTechMedical.com or email [e-mail].




Media Contact
Rob Kirby
G-Tech Medical
[e-mail]

[blakieboy7] 12/1/2022 08:39

Nice start

[the stigologist] 11/1/2022 23:15

I'd say a 50% discount is well earned given the Management and illiquidity and lack of transparency on underlying holdings

[btgman] 11/1/2022 23:04

Interesting day ahead tomorrow NSCI is an absolute gem massively undervalued
AIMHO
GLA
BTG

[blakieboy7] 11/1/2022 20:21

Thanks Mirabeau

[mirabeau] 11/1/2022 19:55

There you go mate -



A deep discount value play

An investment company in early-stage life sciences, healthcare and technology businesses is priced on half analysts' sum-of-the-parts valuations even though its investee companies continue to perform well

January 11, 2022

By Simon Thompson

£1.3m investment in London-based robotics and AI company Q-Bot
$0.73m direct investment in regenerative medicine company EpiBone
Positive trading update from health and life sciences subsidiary ProAxsis
Priced on half analysts’ sum-of-the-parts valuations

NetScientific (NCSI: 88p), an investment company that backs early-stage life sciences, healthcare and technology businesses, has released multiple positive announcements for its investee companies and further diversified its portfolio since my last update (‘Glaring valuation anomaly exposed’, 4 November 2021).

The group has used £1.3m of its cash pile to take an 18.7 per cent............continued

[blakieboy7] 11/1/2022 19:53

Do you have a link Mirabeau?

[mirabeau] 11/1/2022 19:49

Tipped by ST in the IC

[peaky01] 10/1/2022 14:34

Thats a decent rns! Id be hoping worth at least 15% pickup off that

[blakieboy7] 10/1/2022 14:27

NSCI have actually bothered to update the market with the PDSB RNS

[blakieboy7] 10/1/2022 14:26

Ah that's more like it!!

[peaky01] 10/1/2022 14:25

Nice pick up at last. Be happier sat over a quid for now

[blakieboy7] 10/1/2022 13:22

PDSB RNS - FLORHAM PARK, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- PDS BiotechnologyCorporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developingnovel cancer therapies based on the Company's proprietary Versamune(®)T-cell activating technology, today announced that it has been granted U.S.Patent Application No. 15,724,818 titled "Novel HPV16 Non HLA-RestrictedT-cell Vaccines, Composition and Methods of Use Thereof" by the UnitedStates Patent and Trademark Office (USPTO).The newly issued patent covers the PDS0101 immunotherapy which consists of acombination of the Versamune technology platform with a unique mixture ofshort protein fragments derived from the cancer-causing virus, HPV16. Thecomposition promotes the induction of killer (CD8+) T-cells by the immunesystem that recognize, and attack cancers caused by infection with HPV16irrespective of the patients' genetic makeup.

[blakieboy7] 10/1/2022 12:04

And yet this fall further!! Ffs

[blakieboy7] 10/1/2022 07:45

Agreed Peaky and it would be nice to see some of the sellers return

[peaky01] 10/1/2022 07:31

Agreed, lets hope the share price picks up tho today